Aligos Therapeutics bolsters executive team with new VPs By

Aligos Therapeutics bolsters executive team with new VPs By

© Reuters.

SOUTH SAN FRANCISCO – Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company, has announced the immediate appointments of Jordyn Tarazi as Vice President, Investor Relations and Corporate Communications, and Nikhil Aneja as Vice President, Finance. The new hires come as the company prepares for significant clinical data releases later this year.

Jordyn Tarazi brings a background in leadership across investor relations, corporate communications, strategic planning, and business development to Aligos. Her previous role involved establishing a life science incubator at ABio-X Holdings – Inc., and she has experience as the Head of Investor Relations at CohBar, Inc. Tarazi’s early career in investment banking saw her assist companies in raising over $1 billion.

Nikhil Aneja, a Certified Public Accountant (CPA) and Associate Chartered Accountant, has decades of finance and accounting leadership experience. His previous position at CareDx (NASDAQ:), Inc. had him leading a global accounting team and managing all aspects of financial reporting. Aneja’s history includes roles at Global Blood Therapeutics (NASDAQ:), Inc. and ZS Pharma, Inc.

Lesley Ann Calhoun, Executive Vice President, Chief Financial Officer at Aligos, expressed confidence in the strategic growth of the team, which she believes will be instrumental as the company progresses toward its next phase of growth.

Aligos focuses on developing therapies for liver and viral diseases, aiming to address unmet medical needs in areas such as metabolic dysfunction-associated steatohepatitis (MASH) and chronic hepatitis B (CHB). The company was founded in 2018 and has since been working to discover and develop potentially best in class therapeutics.

This news article is based on a press release statement from Aligos Therapeutics, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Related Posts